Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK), Essen, Germany.
Department of Urology, Semmelweis University, Budapest, Hungary; Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Urol Oncol. 2024 Jul;42(7):221.e1-221.e7. doi: 10.1016/j.urolonc.2024.03.011. Epub 2024 Apr 15.
Urachal cancer (UrC) is a rare disease with limited availability of representative incidence and clinical data. Although, the prevalence is accounting for less than 1% of bladder tumors, the 5-year survival rate is around only 50% for patients with resectable tumors, and even worse for patients with metastatic disease. Due to the lack of comprehensive prospective studies, our current knowledge of UrC is still limited.
The present study aimed to summarize the available registry-based studies with unselected UrC patients to evaluate its incidence and clinicopathological characteristics.
We conducted a systematic literature search of registry-based UrC publications on the 15th of May 2023 in 5 databases, which identified 4,748 publications. After duplicate removal and selection by 2 independent investigators, 6 publications proved to be appropriate for the final meta-analysis. Estimated incidence and clinicopathological parameters were extracted.
Estimated incidence ranged between 0.022 and 0.060/ 100.000 person-years, with the highest occurrence in Japan and the lowest in Canada, while the random effect model calculated an overall incidence rate of 0.04 (95%CI: 0.03-0.05) 100.000 person-years. The median age at first diagnosis was 60 years (range: 58-64). The female to male ratio was 2:3. Lymph node or distant metastases were present in 9% and 14% of patients. The predominant tumour type was adenocarcinoma (86%) followed by urothelial carcinoma (12%) and squamous cell carcinoma (2%). The 5-year survival rate was 51.0% with 95%CI: 45.2-57.4.
Our study provides an up-to-date comparison of estimated incidence rates between 6 countries of 3 continents based on rigorously selected registry-based studies. The results suggest low incidence rates for UrC with considerable geographic differences. The present meta-analysis provides unbiased registry-based data on the incidence, clinicopathological parameters and survival of UrC.
脐尿管癌(UrC)是一种罕见疾病,其代表性发病率和临床数据有限。尽管其患病率占膀胱肿瘤的比例不到 1%,但可切除肿瘤患者的 5 年生存率约为 50%,转移性疾病患者的生存率更差。由于缺乏全面的前瞻性研究,我们目前对 UrC 的认识仍然有限。
本研究旨在总结基于登记的、未经选择的 UrC 患者的研究,以评估其发病率和临床病理特征。
我们于 2023 年 5 月 15 日在 5 个数据库中进行了基于登记的 UrC 文献的系统文献检索,共识别出 4748 篇文献。经过 2 位独立研究者的重复去除和选择,有 6 篇文献最终适合进行荟萃分析。提取了估计的发病率和临床病理参数。
估计的发病率在 0.022 至 0.060/100000 人年之间,日本发病率最高,加拿大发病率最低,而随机效应模型计算的总发病率为 0.04(95%CI:0.03-0.05)/100000 人年。首次诊断时的中位年龄为 60 岁(范围:58-64 岁)。男女比例为 2:3。9%和 14%的患者有淋巴结或远处转移。主要肿瘤类型为腺癌(86%),其次是尿路上皮癌(12%)和鳞状细胞癌(2%)。5 年生存率为 51.0%,95%CI:45.2-57.4。
我们的研究基于严格选择的基于登记的研究,提供了 3 大洲 6 个国家之间的最新发病率估计率比较。结果表明,UrC 的发病率较低,且存在显著的地域差异。本荟萃分析提供了基于登记的 UrC 发病率、临床病理参数和生存率的无偏倚数据。